In 2001, the Food and Drug Administration (FDA) approved the use and commercialization of galanthamine, an Amaryllidaceae alkaloid, under its salt form for the palliative treatment of mild to moderate Alzheimer’s disease symptoms due to its potential as an AChE inhibitor [13]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.